Diabetic emergencies remain a significant healthcare challenge in developing countries, presenting a complex intersection of medical, social, and economic issues. This systematic review highlights the concerning prevalence and impact of acute diabetic complications in resource-limited settings.
This systematic review and meta-analysis investigated the effectiveness of triple therapy combinations for treating uncontrolled asthma in adults, with a particular focus on comparing a single inhaler containing beclometasone, formoterol, and glycopyrronium (BDP/FOR/GLY) against other triple therapy options.
The MeMeMe randomized trial studied whether metformin (1,700 mg/day), with or without a Mediterranean diet (MedDiet), could reduce the incidence of major noncommunicable diseases (NCDs) in individuals with metabolic syndrome (MetS). The trial included 1,442 participants, randomly assigned to one of four groups: metformin alone, metformin + MedDiet, placebo alone, or placebo + MedDiet. The participants were followed for an average of three years, with the primary outcome being the cumulative incidence of type 2 diabetes, cardiovascular diseases, and cancer.
Vertex Pharmaceuticals has recently achieved two significant FDA approvals in just 41 days. On December 20, 2024, the FDA approved Alyftrek for treating cystic fibrosis (CF), followed by the approval of Journavx, a novel treatment for moderate-to-severe acute pain, just a few days later.
The FDA has granted approval for Roche’s PATHWAY HER2 (4B5) test to identify HER2-ultralow status in metastatic breast cancer patients, expanding its existing use for detecting HER2-low cases. This approval follows AstraZeneca and Daiichi Sankyo’s recent FDA clearance for Enhertu (trastuzumab deruxtecan) in HER2-ultralow patients, marking a significant advancement in breast cancer treatment. Enhertu is the first HER2-targeting antibody-drug conjugate (ADC) approved for patients with an immunohistochemistry (IHC) score of zero with faint staining in 10% or fewer tumor cells.
